Skip to main content

CeQur Simplicity patients have taken control of their diabetes and found freedom from multiple daily injections, with the effortless, wearable patch for mealtime insulin.

Cequr Simplicity showing on the stomach of a patient illustrating it's convenient

CeQur Simplicity patients have taken control of their diabetes and found freedom from multiple daily injections, with the effortless, wearable patch for mealtime insulin.

Cequr Simplicity showing on the stomach of a patient illustrating it's convenient

Explore Real Stories of Patients Using the CeQur Simplicity Wearable Insulin Patch

Testimonials represent the experiences for each particular patient. Each patients’ experience may differ. CeQur Simplicity is labeled for use in adults over the age of 21 who have been diagnosed with diabetes. The system is not intended for use in pediatric patients.

Patient Educational Videos

Are You Ready to Break Up with Your Insulin Pen?

References

1. Zraick V, Dreon D, Nalk R, Shearer D, Crawford S, Bradford J, Levy B. 2016. Patient User Experience Evaluation of Bolus Patch Insulin Delivery System. Poster presented at the American Diabetes Association’s 76th Scientific Sessions. Abstract 995-P. New Orleans, LA, USA.

2. Bergenstal R, Peyrot M, Dreon D, Aroda V, Bailey T, Brazg R, Frias J, Johnson M, Klonoff D, Kruger D, Ramtoola S, Rosenstock J, Serusclat P, Weinstock R, Naik R, Shearer D, Zraick V, Levy B on behalf of the Calibra Study Group. 2019. Implementation of Basal-Bolus Therapy in Type 2 Diabetes: A Randomized Controlled Trial Comparing Bolus Insulin Delivery Using an Insulin Patch with an Insulin Pen. Diabetes Technology and Therapeutics 21 (5):1-13.

3. Isaacs D, Kruger DF, Shoger E, Chawla H. Patient perceptions of satisfaction and quality of life regarding use of a novel insulin delivery device. Clin Diabetes. 2023;41(2):198-207.

4. Barry, R., D.O.N. Johns, and B. Rees, 2329-PUB: Transitioning T2DM Patients to Basal-Bolus Insulin Leads to Sustainable A1C Improvement. Diabetes, 2019. 68(Supplement 1): p. 2329-PUB. This is a post-hoc analysis done on BergenstalTrial.